SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Erfurth Eva Marie) "

Sökning: WFRF:(Erfurth Eva Marie)

  • Resultat 61-70 av 71
  • Föregående 1...23456[7]8Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Ragnarsson, Oskar, et al. (författare)
  • The incidence of Cushing’s disease : a nationwide Swedish study
  • 2019
  • Ingår i: Pituitary. - : Springer. - 1386-341X .- 1573-7403. ; 22:2, s. 179-186
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Studies on the incidence of Cushing’s disease (CD) are few and usually limited by a small number of patients. The aim of this study was to assess the annual incidence in a nationwide cohort of patients with presumed CD in Sweden. Methods: Patients registered with a diagnostic code for Cushing’s syndrome (CS) or CD, between 1987 and 2013 were identified in the Swedish National Patient Registry. The CD diagnosis was validated by reviewing clinical, biochemical, imaging, and histopathological data. Results: Of 1317 patients identified, 534 (41%) had confirmed CD. One-hundred-and-fifty-six (12%) patients had other forms of CS, 41 (3%) had probable but unconfirmed CD, and 334 (25%) had diagnoses unrelated to CS. The mean (95% confidence interval) annual incidence between 1987 and 2013 of confirmed CD was 1.6 (1.4–1.8) cases per million. 1987–1995, 1996–2004, and 2005–2013, the mean annual incidence was 1.5 (1.1–1.8), 1.4 (1.0–1.7) and 2.0 (1.7–2.3) cases per million, respectively. During the last time period the incidence was higher than during the first and second time periods (P < 0.05). Conclusion: The incidence of CD in Sweden (1.6 cases per million) is in agreement with most previous reports. A higher incidence between 2005 and 2013 compared to 1987–2004 was noticed. Whether this reflects a truly increased incidence of the disease, or simply an increased awareness, earlier recognition, and earlier diagnosis can, however, not be answered. This study also illustrates the importance of validation of the diagnosis of CD in epidemiological research.
  •  
62.
  • Rosilio, M, et al. (författare)
  • Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H)
  • 2004
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - : Oxford University Press. - 1945-7197. ; 89:4, s. 1684-1693
  • Tidskriftsartikel (refereegranskat)abstract
    • Questions on Life Satisfaction-Hypopituitarism (QLS-H) is a new quality-of-life (QoL) questionnaire developed for adults with hypopituitarism. To determine the effects of long-term GH treatment on QoL, we evaluated QLS-H Z-scores in 576 adult patients with GH deficiency (GHD) enrolled in HypoCCS, an international observational study, using data from five countries in which comparative QLS-H data from the general population were available. Baseline QLS-H Z-scores were significantly lower in GH-deficient patients than in the general population of the same age, gender, and nationality. Z-scores were also significantly lower in female patients vs. males (P=0.006) and in adult-onset vs. childhood-onset GHD (P=0.002). Multivariate analysis associated female gender, multiple pituitary hormone deficiencies, low serum IGF-I values (<75 μg/liter), and concomitant antidepressant medication with low baseline Z-scores. QLS-H Z-scores increased from -1.02&PLUSMN;1.43 (SD) at baseline to -0.25&PLUSMN;1.34 (SD) after 1 yr of GH treatment (P<0.001) and were no longer significantly different from the general population after 4 yr of treatment. There was no correlation between change in Z-score and GH dose or changes in IGF-I and IGF binding protein-3 during treatment. This study demonstrates that 1) improvements in QoL, as measured by the QLS-H, are maintained during long-term GH replacement therapy of adults with GHD, and 2) the QLS-H is a useful tool for evaluating QoL in hypopituitary patients treated in clinical practice. The authors suggest that evaluation of QoL should be a part of the routine clinical management of adult GH-deficient patients, complementing the measurement of surrogate biological markers or other clinical end points.
  •  
63.
  • Rylander, Lars, et al. (författare)
  • Associations between CB-153 and p,p'-DDE and hormone levels in serum in middle-aged and elderly men.
  • 2006
  • Ingår i: Chemosphere. - : Elsevier. - 1879-1298. ; 65:3, s. 375-381
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Animal and epidemiologic data indicate that exposure to persistent organochlorine pollutants (POPs) may disrupt the hypothalamus-pituitary-thyroid (HPT) and the hypothalamus-pituitary-gonadal (HPG) axes. We have assessed whether the POP-biomarkers 2,2'4,4',5,5'-hexachlorobiphenyl (CB-153) and 1,1-dichloro-2,2-bis(4-chlorophenyl)-ethene (p,p'-DDE) affect thyrotropin (TSH), thyroid hormones, gonadotropins or sex hormone concentrations in men. Methods: Lipid adjusted serum concentrations of CB-153, and p,p'-DDE, were determined in 196 men (median age 59 years, range 48-82). Hormone analyses in serum were performed with immunoassays. The effect of CB-153 and p,p'-DDE (as continuous or categorized variables) were evaluated by linear regression models, adjusting for potential confounders. Results: There was a significant positive association between p,p'-DDE and TSH. An increase of 100 ng/g lipid of p,p'-DDE corresponded to an increase of 0.03 mU/l (95% Confidence Interval (CI) 0.01, 0.05) in TSH level. The explanatory value (R 2) of the multi-variate model was only 7%. Moreover, there was a significant negative association between p,p'-DDE and estradiol. An increase of 100 ng/g lipid of p,p'-DDE corresponded to a decrease of 0.57 pmol/l (95% CI -1.0, -0.12) in estradiol level. The R-2-value was only 4%. No associations were observed between any of the POP biomarkers and the other hormones. Conclusions: The positive association between p,p'-DDE and TSH and the negative association between p,p'-DDE and estradiol, among middle-aged and elderly men, were not accompanied by associations between the POP-markers and thyroxin, testosterone, and gonadotropins, respectively. The results gives some additional support for that POP exposure may affect HPT- and HPG-axes also in humans, but the overall epidemiological data are still not coherent enough to allow any firm conclusions. (c) 2006 Elsevier Ltd. All rights reserved.
  •  
64.
  •  
65.
  • Svärd, Daniel, et al. (författare)
  • Cognitive interference processing in adult survivors of childhood acute lymphoblastic leukemia using functional magnetic resonance imaging
  • 2021
  • Ingår i: Acta Oncologica. - : Taylor & Francis. - 1651-226X.
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Childhood acute lymphoblastic leukemia (ALL) is associated with cognitive impairment in adulthood. Cognitive interference processing and its correlated functional magnetic resonance imaging (fMRI) activity in the brain have not yet been studied in this patient group.Material: Twenty-six adult childhood ALL survivors (median [interquartile range {IQR}] age, 40.0 [37.0-42.3] years) were investigated at median age (IQR), 35.0 (32.0-37.0) years after treatment with intrathecal and intravenous chemotherapy as well as cranial radiotherapy (24 Gy) and compared with 26 matched controls (median [IQR] age, 37.5 [33.0-41.5] years).Methods: Cognitive interference processing was investigated in terms of behavioral performance (response times [ms] and accuracy performance [%]) and fMRI activity in the cingulo-fronto-parietal (CFP) attention network as well as other parts of the brain using the multisource interference task (MSIT).Results: ALL survivors had longer response times and reduced accuracy performance during cognitive interference processing (median [IQR] interference effect, 371.9 [314.7-453.3] ms and 6.7 [4.2-14.7]%, respectively) comparedwith controls (303.7 [275.0-376.7] ms and 2.3 [1.6-4.3]%, respectively), but did not exhibit altered fMRI activity in the CFP attention network or elsewhere in the brain.Conclusion: Adult childhood ALL survivors demonstrated impaired behavioral performance but no altered fMRI activity when performing cognitive interference processing when compared with controls. The results can be used to better characterize this patient group and to optimize follow-up care and support for these individuals.
  •  
66.
  • Svärd, Daniel, et al. (författare)
  • Cognitive interference processing in adults with childhood craniopharyngioma using functional magnetic resonance imaging
  • 2021
  • Ingår i: Endocrine. - : Humana Press. - 1355-008X. ; 74:3, s. 714-722
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: To assess cognitive interference processing in adults with childhood craniopharyngioma (CP), with and without hypothalamic injury, respectively, in terms of behavioral performance and functional magnetic resonance imaging (fMRI) activity, using the multi-source interference task (MSIT).METHODS: Twenty-eight CP patients (median age 34.5 [29.0-39.5] years) were investigated at median 20.5 (16.3-28.8) years after treatment with surgical resection and in some cases additional radiotherapy (n = 10) and compared to 29 matched controls (median age 37.0 [32.5-42.0] years). The subjects performed the MSIT during fMRI acquisition and behavioral performance in terms of response times (ms) and accuracy performance (%) were recorded.RESULTS: The MSIT activated the cingulo-fronto-parietal (CFP) attention network in both CP patients and controls. No differences were found in behavioral performance nor fMRI activity between CP patients (interference effect 333.9 [287.3-367.1] ms and 3.1 [1.6-5.6]%, respectively) and controls (309.1 [276.4-361.0] ms and 2.6 [1.6-4.9]%). No differences were found in behavioral performance nor fMRI activity between the two subgroups with (332.0 [283.6-353.4] ms and 4.2 [2.3-5.7]%, respectively) and without hypothalamic injury (355.7 [293.7-388.7] ms and 2.1 [1.0-5.2]%, respectively), respectively, and controls.CONCLUSION: Adults with childhood CP performed cognitive interference processing equally well as controls and demonstrated no compensatory fMRI activity in the CFP attention network compared to controls. This was also true for the two subgroups with and without hypothalamic injury. The results can be useful to better characterize this condition, and to optimize treatment and support for these individuals.
  •  
67.
  •  
68.
  • van Bunderen, Christa C., et al. (författare)
  • Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity
  • 2014
  • Ingår i: Clinical Endocrinology. - : Wiley-Blackwell. - 1365-2265. ; 81:1, s. 1-14
  • Forskningsöversikt (refereegranskat)abstract
    • Due to the positive effects demonstrated in randomized clinical trials on cardiovascular surrogate markers and bone metabolism, a positive effect of growth hormone (GH) treatment on clinically relevant end-points seems feasible. In this review, we discuss the long-term efficacy and safety of GH treatment in adult patients with growth hormone deficiency (GHD) with emphasis on morbidity: fatal and nonfatal cardiovascular disease (CVD) and stroke, fractures, fatal and nonfatal malignancies and recurrences, and diabetes mellitus. A positive effect of GH treatment on CVD and fracture risk could be concluded, but study design limitations have to be considered. Stroke and secondary brain tumours remained more prevalent. However, other contributing factors have to be taken into account. Regrowth and recurrences of (peri) pituitary tumours were not increased in patients with GH treatment compared to similar patients without GH treatment. All fatal and nonfatal malignancies were not more prevalent in GH-treated adults compared to the general population. However, follow-up time is still relatively short. The studies on diabetes are difficult to interpret, and more evidence is awaited. In clinical practice, a more individualized assessment seems appropriate, taking into consideration the underlying diagnosis of GHD, other treatment regimens, metabolic profile and the additional beneficial effects of GH set against the possible risks. Large and thoroughly conducted observational studies are needed and seem the only feasible way to inform the ongoing debate on health care costs, drug safety and clinical outcomes.
  •  
69.
  •  
70.
  • Woodmansee, Whitney W., et al. (författare)
  • Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS
  • 2013
  • Ingår i: European Journal of Endocrinology. - : Society of the European Journal of Endocrinology. - 1479-683X. ; 168:4, s. 565-573
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors. We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (< 3 years), longer observation is recommended. Nevertheless, clinicians should be alerted to the possibility of increased risk of SN in childhood cancer survivors treated with GH and continue chronic surveillance. European Journal of Endocrinology 168 565-573
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 71
  • Föregående 1...23456[7]8Nästa
Typ av publikation
tidskriftsartikel (59)
konferensbidrag (6)
forskningsöversikt (5)
bokkapitel (1)
Typ av innehåll
refereegranskat (71)
Författare/redaktör
Erfurth, Eva Marie (71)
Link, Katarina (10)
Hagmar, Lars (10)
Ekman, Bertil (10)
Björk, Jonas (8)
Rylander, Lars (8)
visa fler...
Bülow, Birgitta (8)
Österberg, Kai (6)
Ahrén, Bo (5)
Burman, Pia (5)
Johannsson, Gudmundu ... (5)
Lätt, Jimmy (5)
Zimmermann, Alan G (5)
Mikoczy, Zoli (4)
van Westen, Danielle (4)
Petersén, Åsa (4)
Mårtensson, Johan (4)
Cavallin-Ståhl, Eva (4)
Örbaek, Palle (4)
Bramnert, Margareta (4)
Thorén, Marja (4)
Hellerstedt, Robin (4)
Abs, Roger (3)
Bengtsson, Bengt-Ake (3)
Verhelst, Johan (3)
Sundgren, Pia (3)
Johannsson, Gudmundu ... (3)
Olsson, Tommy (3)
Bensing, Sophie (3)
Persson, Roger (3)
Svensson, Johan (3)
Wiebe, Thomas (3)
Papakokkinou, Eleni (3)
Petersson, Maria (3)
Bryngelsson, Ing-Lis ... (3)
Thilén, Ulf (3)
Schwarcz, Erik (3)
Robison, Leslie L. (3)
Wahlberg, Jeanette (3)
Höybye, Charlotte (3)
Gabery, Sanaz (3)
Berinder, Katarina (3)
Dahlqvist, Per (3)
Edén Engström, Britt (3)
Hoybye, Charlotte (3)
Rosén, Thord (3)
Elfving, Maria (3)
Child, Christopher J ... (3)
Woodmansee, Whitney ... (3)
Åkerman, Anna-Karin (3)
visa färre...
Lärosäte
Lunds universitet (68)
Linköpings universitet (5)
Göteborgs universitet (4)
Umeå universitet (4)
Uppsala universitet (3)
Karolinska Institutet (1)
Språk
Engelska (71)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (68)
Samhällsvetenskap (3)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy